These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16781242)

  • 21. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?
    Glasziou PP; Eckermann SD; Mulray SE; Simes RJ; Martin AJ; Kirby AC; Hall JP; Caleo S; White HD; Tonkin AM
    Med J Aust; 2002 Oct; 177(8):428-34. PubMed ID: 12381252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction.
    Newby LK; Eisenstein EL; Califf RM; Thompson TD; Nelson CL; Peterson ED; Armstrong PW; Van de Werf F; White HD; Topol EJ; Mark DB
    N Engl J Med; 2000 Mar; 342(11):749-55. PubMed ID: 10717009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction.
    Goldman L; Sia ST; Cook EF; Rutherford JD; Weinstein MC
    N Engl J Med; 1988 Jul; 319(3):152-7. PubMed ID: 2898733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.
    Ashraf T; Hay JW; Pitt B; Wittels E; Crouse J; Davidson M; Furberg CD; Radican L
    Am J Cardiol; 1996 Aug; 78(4):409-14. PubMed ID: 8752184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pravastatin in acute ischaemic syndromes: results of a randomised placebo-controlled trial.
    Den Hartog FR; Van Kalmthout PM; Van Loenhout TT; Schaafsma HJ; Rila H; Verheugt FW
    Int J Clin Pract; 2001 Jun; 55(5):300-4. PubMed ID: 11452676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Could a federal program to promote influenza vaccination among elders be cost-effective?
    Patel MS; Davis MM
    Prev Med; 2006 Mar; 42(3):240-6. PubMed ID: 16480761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment and prognosis after acute coronary syndrome in an unselected patient population].
    Jensen LO; Thayssen P
    Ugeskr Laeger; 2007 Feb; 169(6):492-7. PubMed ID: 17303028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
    Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
    Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
    Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study].
    Lange AP; Szucs TD
    Med Klin (Munich); 2004 Sep; 99(9):500-5. PubMed ID: 15372179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cost-effectiveness of pharmacologic treatments for the reduction of blood lipids].
    Plans Rubió P; Rovira Forns J
    Med Clin (Barc); 1995 Sep; 105(9):327-33. PubMed ID: 7500685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
    Alexander KP; Newby LK; Cannon CP; Armstrong PW; Gibler WB; Rich MW; Van de Werf F; White HD; Weaver WD; Naylor MD; Gore JM; Krumholz HM; Ohman EM; ;
    Circulation; 2007 May; 115(19):2549-69. PubMed ID: 17502590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
    Alexander KP; Newby LK; Armstrong PW; Cannon CP; Gibler WB; Rich MW; Van de Werf F; White HD; Weaver WD; Naylor MD; Gore JM; Krumholz HM; Ohman EM; ;
    Circulation; 2007 May; 115(19):2570-89. PubMed ID: 17502591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
    Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
    Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
    Neil HA; DeMicco DA; Luo D; Betteridge DJ; Colhoun HM; Durrington PN; Livingstone SJ; Fuller JH; Hitman GA;
    Diabetes Care; 2006 Nov; 29(11):2378-84. PubMed ID: 17065671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness of a smoking cessation program in patients admitted for coronary heart disease.
    Quist-Paulsen P; Lydersen S; Bakke PS; Gallefoss F
    Eur J Cardiovasc Prev Rehabil; 2006 Apr; 13(2):274-80. PubMed ID: 16575284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
    Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.